Atlas Capital Advisors LLC Increases Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Atlas Capital Advisors LLC boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2,385.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,126 shares of the medical equipment provider’s stock after acquiring an additional 3,960 shares during the period. Atlas Capital Advisors LLC’s holdings in Zimmer Biomet were worth $448,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ZBH. TD Asset Management Inc raised its stake in Zimmer Biomet by 10.1% in the fourth quarter. TD Asset Management Inc now owns 169,595 shares of the medical equipment provider’s stock valued at $20,640,000 after buying an additional 15,552 shares in the last quarter. Bank of Nova Scotia grew its stake in Zimmer Biomet by 499.0% during the 4th quarter. Bank of Nova Scotia now owns 134,729 shares of the medical equipment provider’s stock worth $16,397,000 after buying an additional 112,237 shares during the last quarter. Speece Thorson Capital Group Inc. increased its position in Zimmer Biomet by 13.8% during the fourth quarter. Speece Thorson Capital Group Inc. now owns 158,202 shares of the medical equipment provider’s stock worth $19,253,000 after buying an additional 19,144 shares during the period. APG Asset Management US Inc. purchased a new stake in Zimmer Biomet in the fourth quarter valued at approximately $14,530,000. Finally, M&G Plc acquired a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $7,397,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $115.47 on Friday. The company has a market capitalization of $23.76 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 2.04 and a beta of 1.01. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $133.90. The company’s 50 day simple moving average is $109.61 and its 200 day simple moving average is $117.44.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.02. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.82 earnings per share. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.06 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ZBH shares. Raymond James lowered their price objective on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Argus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Tuesday, May 21st. Barclays decreased their price target on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a report on Friday, May 31st. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, Citigroup lowered their target price on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $126.41.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.